Sparsentan en pacientes con nefropatía IgA

Abstract

Immunoglobulin type A-mediated nephropathy (IgAN) is considered to be the main cause of primary glomerulonephritis. It derives from an accumulation of IgA deposits in the mesangium of the renal glomerulus. Its clinical presentation will depend on each patient’s characteristics, being asymptomatic in the early stages and, in some cases, progressing to chronic renal disease. To date, there is no definitive treatment, so the management proposed by the current guidelines focuses on preserving renal function through supportive therapy in conjunction with pharmacological treatment. The first pillar of treatment includes patient education about their disease, lifestyle changes, mandatory and continuous blood pressure monitoring, and antihypertensive medications. A new drug under study, Filspari “Sparsentan,” is indicated for adults with IgAN to prevent progression to chronic kidney disease. It is a selective, non-immunosuppressive, dual-acting single-molecule antagonist with a high degree of selectivity for Angiotensin II receptors and for endothelin A (ET-1) receptors. The results showed a decrease in proteinuria and a slow decline in glomerular filtration rate. In conclusion, Sparsentan stands out as a non-immunosuppressive drug with antiproteinuric and nephroprotective benefits that significantly improve the negative impact on long-term renal function in patients with IgA nephropathy.